BPMC

Blueprint Medicines (BPMC)

Blueprint Medicines Corporation

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:BPMC

<< 前へ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2023/02/15	02 : 41	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/02/10	22 : 49	Dow Jones News	Blueprint Medicines BLU-222 Study on FDA Partial Hold	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/02/10	22 : 27	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/02/10	22 : 00	PR Newswire (US)	Blueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/02/09	22 : 25	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/02/09	22 : 00	PR Newswire (US)	Blueprint Medicines to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/02/08	06 : 01	PR Newswire (US)	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/02/07	04 : 50	Edgar (US Regulatory)	Schedule 13g (sc 13g/a)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/02/03	23 : 00	PR Newswire (US)	Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/01/26	22 : 55	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/01/23	22 : 51	Dow Jones News	Blueprint Medicines Gets FDA Priority Review for Ayvakit in Indolent Systemic Mastocytosis	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/01/23	22 : 00	PR Newswire (US)	Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/01/20	23 : 46	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/01/10	07 : 17	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/01/10	07 : 14	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/01/09	22 : 31	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/01/06	23 : 00	PR Newswire (US)	Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/01/05	22 : 00	PR Newswire (US)	Blueprint Medicines Provides 2023 Portfolio Goals to Achieve Precision at Scale	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/01/05	06 : 01	PR Newswire (US)	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BPMC	Blueprint Medicines Corporation
2022/12/28	06 : 28	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:BPMC	Blueprint Medicines Corporation
2022/12/12	20 : 15	TipRanks	Berenberg Bank Sticks to Its Buy Rating for Blueprint Medicines (BPMC)	NASDAQ:BPMC	Blueprint Medicines Corporation
2022/12/07	06 : 17	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:BPMC	Blueprint Medicines Corporation
2022/12/06	07 : 01	PR Newswire (US)	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BPMC	Blueprint Medicines Corporation
2022/11/23	06 : 36	PR Newswire (US)	Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis	NASDAQ:BPMC	Blueprint Medicines Corporation
2022/11/10	06 : 01	PR Newswire (US)	Blueprint Medicines to Present at Upcoming Investor Conferences	NASDAQ:BPMC	Blueprint Medicines Corporation
2022/11/10	05 : 22	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:BPMC	Blueprint Medicines Corporation
2022/11/08	06 : 10	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:BPMC	Blueprint Medicines Corporation
2022/11/05	05 : 01	PR Newswire (US)	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BPMC	Blueprint Medicines Corporation
2022/11/04	13 : 55	TipRanks	Robert W. Baird Reaffirms Their Buy Rating on Blueprint Medicines (BPMC)	NASDAQ:BPMC	Blueprint Medicines Corporation
2022/11/03	22 : 00	PR Newswire (US)	Blueprint Medicines to Present New Data Reinforcing Clinical Leadership in Systemic Mastocytosis at 2022 ASH Annual Meeting	NASDAQ:BPMC	Blueprint Medicines Corporation